The Notion: 5pt BRAND conversation is a brand conversation that is designed to engage consumers with products and services. Effective communication design creates a dialogue and encourages the consumer to start a conversation about their experience in the brand community.

1. !
"#$%&''' ()*+,-./01)*
communication design that starts a conversation
CHRISTY SCHWINDT

2. !
"#$%&''' ()*+,-./01)*
! Strategy + Opportunity
5pt BRAND conversation
! Brand Mission
The Mission: To design a brand that drives and motivates
consumers.
The Notion: 5pt BRAND conversation is a brand
!
conversation that is designed to engage consumers with
Define Brand Community products and services. Effective communication design
creates a dialogue and encourages the consumer to
start a conversation about their experience in the brand
!
community.
Develop Identity “To grow now, companies must innovate and perform on
every level, and that is where design comes into play.”
- Warren Berger
! Communication Design

3. !
"#$%&''' ()*+,-./01)*
Case Study: iC42
C42
www.bioanalytics.us
integrated solutions in systems biology
clinical research & development

4. !
"#$%&''' ()*+,-./01)*
! Strategy: To become a leader in bioanalytical services.
Opportunity: Brand the service center and introduce it’s
capabilities to the iC42 community. Case Study: iC42
! Brand Mission: To serve science with integrated solutions
to systems biology.
! iC42 Brand Community
University of Colorado
Research Community
C42
www.bioanalytics.us
integrated solutions in systems biology
clinical research & development
Global Collaborations
Novartis
Siemens
Thermofisher
Kaiser
Pain Clinics
Toxicology Patients
Vitamin D Patients
Transplant Patients
Pediatric Pharmacology
!
Develop Identity: Trademarked Brand : iC42
Trademarked Mark for Commerce
Trademarked IP for iC42
Trademarked Colors: Custom Yellow, Gray & Black
Typography: Myraid Pro

5. ! !
Communication Design: Business Cards
"#$%&''' ()*+,-./01)*
Case Study: iC42
C42
www.bioanalytics.us
integrated solutions in systems biology
clinical research & development
•Highly Sensitive HPLC, LC-MS, GC-MS Bioanalytics
•Complex Assay Development & Validation
•GLP Compliant, CAP Accredited, CLIA Certi ed
•Quanti cation of Drugs & Metabolites
Uwe Christians, MD, PhD, MRQA •Isolation of Drug Metabolites & Structural ID
Professor & Laboratory Director •Clinical Therapeutic Drug Monitoring
•Complete PK/PD Package Managed Under One Roof
SEND SAMPLES TO: •Molecular Marker Discovery, Quali cation
Bioscience East, Suite 100 & Development
1999 North Fitzsimons Parkway •Consulting & Strategic Research Partnerships
Aurora, CO 80045-7503
email: uwe.christians@ucdenver.edu phone: 303.724.5665 www.bioanalytics.us
Communication Design: Highlights from 35 page Service Catalog
C42
www.bioanalytics.us
integrated solutions in systems biology
clinical research & development C42
www.bioanalytics.us
integrated solutions in systems biology
clinical research & development
1.1 Quantitative Bioanalytical Methods
Compound Matrix Sensitivity Instrument
ADMA, Homocysteine, Arg Plasma 0.3 M API 4000
Quantitative Bioanalytical Methods
Compounds
Alfentanil Plasma 0.1 ng/mL API 5000
Aprotinin Tissue (Rat Kidney) 80 ng/mL ELISA
Biolimus Blood, Tissue, Stents 0.05 ng/mL API 5000
Cyclosporine / Metabolites Blood 0.1-1.0 ng/mL API 5000
DMXB Plasma/Brains 0.1 ng/mL API 5000
Duet DNA Monocytes Ratio GC-MS
Everolimus Blood 0.1 ng/mL API 5000
Felbamate CSF, Brain, Serum 0.1 ng/mL API 5000
Fentanyl Plasma 0.01 ng/mL API 4000
Free-Fatty Acids Plasma, Tissue, Blood 100 M GC-MS
GSH Plasma 10 M API 4000
Glucocorticiods Plasma 0.1 ng/mL API 5000
[13C] Glucose Plasma 10 M GC-MS
[13C] Glycerol Plasma 10 M GC-MS
High Energy Phosphates Tissues 0.25 M API 4000
Summary of Services Isoprostanes
Ketamine
Ketarolac
Plasma, Urine
Blood
Plasma
0.01 ng/mL
1.0 ng/mL
1.0 ng/mL
API 5000
UPLC-MS/MS
API 4000
Lamotrigine Plasma 1.0 ng/mL API 4000
Le unomide Blood 0.1 ng/mL API 5000
Lidocaine Plasma 0.5 ng/mL API 4000
Lovastatin Plasma 0.1 ng/mL API 5000
Metabolic Pro ling Plasma, Urine, Tissue _______ Exactive
Morphine / Metabolites Plasma 0.25 - 2.5 ng/mL API 5000
MPA Plasma 1.0 ng/mL API 4000
Naltrexone Plasma 0.1 ng/mL API 5000
Nicotine Hair 0.1 ng/mL API 5000
Pravastatin Plasma 0.5 ng/mL API 4000
Phenytoin Plasma 0.1 ng/mL API 5000
PhIP Plasma / Microsomes 0.1 ng/mL API 4000
Bioscience East, Suite 100 Propofol Plasma 0.5 ng/mL API 4000
1999 North Fitzsimons Parkway Sirolimus Tissues / Blood 0.01 ng/mL API 4000
Aurora, CO 80045-7503
Steroid Hormones Plasma 0.1 ng/mL API 5000
303-724-5665
Tacrolimus / Metabolites Blood 0.1 ng/mL API 4000
Temsirolimus / Metabolites Blood 0.1 ng/mL Exactive
Valproic Acid Serum 1.0 ng/mL GC/MS
Summary of Bioanalytical Services Summary of Services
iC42 Colorado, June 2010 iC42 Colorado, June 2010 Vitamin D and Metabolites Plasma 0.1 ng/mL API 5000 7

6. "#$%&''' ()*+,-./01)* !
Case Study: iC42
Communication Design: Email Announcements Communication Design: Student Program Letter
Did you know that a comprehensive bioanalytics lab is available to you and is located
on the University of Colorado’s Premier Medical Campus?
C42
www.bioanalytics.us
integrated solutions in systems biology
clinical research & development
Welcome, we thank you for your interest in iC42.
We are looking forward to supporting you and assisting you with your clinical trials as well as
providing state-of the-art bioanalytical services. In addition, we are offering you world-class training in
clinical research and development. At iC42, you will find abundant opportunities to participate in
Highly Sensitive HPLC, LC-MS, GC-MS Bioanalytics clinical, translational and benchtop research activities.
Complex Assay Development & Validation
GLP Compliant, CAP Accredited, CLIA Certi ed SEND SAMPLES TO OR VISIT US AT: iC42 Clinical Research & Development is a regulatory compliant mass spectrometry laboratory (cGLP
Quanti cation of Drugs & Metabolites Bioscience East, Suite 100 complaint, CAP accredited and CLIA certified) with currently 17 mass spectrometers and is part of the
Isolation of Drug Metabolites & Structural ID 1999 North Fitzsimons Parkway Department of Anesthesiology. We are a unique clinical research and development facility that
Clinical Therapeutic Drug Monitoring Aurora, CO 80045-7503 combines quantitative mass spectrometry (drugs, drug metabolites, other small molecules and large
Complete PK/PD Package Managed Under One Roof molecules, endogenous compounds), metabolic and protein profiling technologies all under one roof.
Molecular Marker Discovery, Quali cation
& Development We are designed and uniquely qualified to carry out the bioanalytics for complex clinical trials
involving drug quantification and molecular marker strategies. In addition, iC42 carries out research
Consulting & Strategic Research Partnerships
and development projects including: molecular marker discovery and qualification, translational
research, strategy development and the identification of molecular mechanisms. Projects range from
For more information or to schedule a lab tour please email: the development and validation of assays and strategies with only a few study samples and clinical
therapeutic drug monitoring to serving as the central laboratory for phase III clinical trials with more
christy.schwindt@ucdenver.edu
than 50 clinical centers and more than ten thousand samples. In addition to research and
bioanalytical services, activities include consulting and interactions with regulatory agencies.
iC42 is committed to advancing individual medicine by examining the unique biology of an individual
to assess truly personalized treatments. Other major foci are the evaluation of pediatric
pharmacokinetics, the development of clinical management tools for pediatric patients, advancement
in transplantation and drug metabolism. In addition, we promote and enhance research through the
Colorado Center for Transplantation Care, Research and Education and the Colorado Center for the
Advancement of Pediatric Pharmacology.
For additional information please contact:
Jaimie Henthorn
303-724-5663
jaimie.henthorn@ucdenver.edu
and please visit us at www.bioanalytics.us
Sincerely,
Uwe Christians MD, PhD, MRQA
iC42 Laboratory Director
“Where the future is made today…” - Dr. Bunsen Honeydew

7. Communication Design: USB Business Cards
"#$%&''' ()*+,-./01)* !
Case Study: iC42
C42 www.bioanalytics.us
C42 www.bioanalytics.us
SEND SAMPLES TO:
Bioscience East, Suite 100
1999 North Fitzsimmons Parkway
Aurora, CO 80045
(303) 724-5665
Communication Design: 8” x 8” Marketing Conference Cards
pediatric
pharmacokinetics
Dr. Galinkin is a leader in the eld of Pediatric Pharmacology and Anesthesiology, he
is a leader in pediatric research here at the University of Colorado.
Internationally, Dr. Galinkin is recognized for his expertise in pediatric pharmacokinetics. He
discover
integrity intelligence innovation
integrated solutions in systems biology
Extensive Experience &
Interactions with Small Biotech
C42 clinical research & development
integrated Solutions in Systems biology
biotech pharmaceutical academia
regularly lectures at international scienti c meetings and locally on drug pharmacokinetics. Companies
He has designed and conducted many clinical studies in all stages of clinical development and We are a unique comprehensive facility that combines quantitative mass spectrometry,
has served on multiple steering committees for multi center trials and for multiple
contact
Bench top-to-Bed Drug metabolic and protein pro ling technologies in a regulatory compliant environment.
pharmaceutical company studies. Metabolism Studies We are designed and uniquely quali ed to carry out the bioanalytics for complex
clinical trials involving drug quanti cation and molecular marker strategies. In
C42
Locally, Dr. Galinkin is one of the Chairs of the IRB for the University of Colorado. He also co-
Consulting & Strategic Research addition, iC42 carries out research and development projects including: molecular
chairs the Scienti c Advisory Committee for the University of Colorado’s Clinical Translational Partnerships marker discovery & quali cation, translational research, strategy development and the
Science Institute, a NIH funded vehicle that provides infrastructure to clinical investigators
identi cation of molecular mechanisms. Projects range from the development and
throughout the University. Additionally, Dr. Galinkin is the Chair of the Pharmacy and Complete Molecular Marker validation of bioanalytical assays and strategies to serving as the central bioanalytical
Therapeutics Committee at The Children’s Hospital. Discovery, Quali cation & laboratory for phase III clinical trials with more than 50 clinical centers and more than
contact us for... www.bioanalytics.us
Development ten thousand samples. In addition to research and bioanalytical services, activities
include consulting and interactions with regulatory agencies.
design & conduct of Clinical Therapeutic Drug
pediatric pharmacokinetics
Monitoring
pharmacogenomics pharmocokinetics pharmacodynamics phone: 303-724-5665
clinical trials in pediatric populations Novel Translational Technologies
drug metabolism phase I clinical trials
email: christy.schwindt@ucdenver.edu in a GLP-Compliant Environment
highly sensitive LC/MS assays in low volume samples
predictivedrug eluting stents
biomarkers
Complete PK/PD package
in a regulatory compliant environment Managed “Under One Roof”
bioanalytics in plasma samples &
dry blood spots on lter paper
visit us at Bioscience East, Suite 100
1999 N. Fitzsimons Parkway
Complex Assay Developments &
Validations metabolomics
development of new pain management strategies
population pharmacokinetics pediatric drug metabolism studies
Aurora, CO 80045
High-Impact Publications &
Presentations pk/pd studies proteomics
www.bioanalytics.us
isolation of drug metabolites
!"##$%&#$'(%()#*$+,($-.//0$1$2,34
phone: 303.724.5665 email: christy.schwindt@ucdenver.edu

8. Communication Design: Interior Signage
!
"#$%&''' ()*+,-./01)*
Case Study: iC42
C42
www.bioanalytics.us
integrated solutions in systems biology
clinical research & development
50”w x 20”h Entry Wall color on clear vinyl
50” x 20” Entry Wall color on clear vinyl
discover integrated solutions in systems biology
15” diameter color LOGO on clear vinyl
to be used on all (5) entry doors. Needs to be removable
20” diameter color LOGO on clear vinyl
15”w x 8”h Entry Door color on clear vinyl
to be used on all (5) interior windows. Needs to be removable
15”width x 8”height color on clear vinyl

9. 5. Communication Design: Website
"#$%&''' ()*+,-./01)* !
Case Study: iC42
When you roll over the logo with the cursor the i’s spins clockwise
iC42 Homepage Design 3/12/11 2:53 PM and our 3 key words pop out:
individualized medicine, innovation, intelligence,
Current logo
individualized medicine
innovation
intelligence
C42
www.bioanalytics.us
integrated solutions in systems biology
clinical research & development
!
!!!!!!!! !!!!!
LABORATORY REQUISITION
SERVICE REQUESTED BY: !!!!!!!!!!!!!!!!!! BILLING INFORMATION: !
! Name ! ! ! ! ! ! !! Name! ! ! ! ! ! ! ! ! ! ! !
Address ! Address !
Phone Phone
Email ! !
Email ! ! !
! !
Budget
!!
!
PROFORMA INVOICE WILL BE SENT
! ! ! SEND SAMPLES TO:
CHECKLIST BEFORE SENDING SAMPLES:
PO or Service Agreement accepted by iC42 iC42 Laboratory
Samples Inventory (excel) emailed to iC42 before samples are shipped ATTN: SAMPLE DEPT
Laboratory Requisition Form included with samples that are shipped Bioscience East, Suite 100
1999 Fitzsimons Pkwy
all correspondence to uwe.christians@ucdenver.edu Aurora, CO 80045
!
phone 303-724-5665
!
!
SPECIMEN INFORMATION
!
Routine!! Stat!
# of Samples sent:!"""""""""""""""!
! Sample Matrix:! ! URINE! ! PLASMA ! SALIVA
!
! ! !
Storage Instructions:_________________________________ Freezer Location/Intials___________________(iC42)
Test Requested:!!!
!
Bioanalytical Analysis Vitamin D Therapeutic Panels Clinical Therapeutic Monitoring
!
please specify: please specify: please specify:
!
Additional test(s) requested: """""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""
!
!"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""
!
REPORTING INFORMATION !
! ! ! ! ! ! ! !
! EMAIL FAX OTHER Additional Report(s) to:!"""""""""""""""""""""""""""""""""""""!
!
!
Please SEND Report(s) to:
! ! !
Phone: """"""""""""""""""""!!!Fax: """"""""""""""""""""!
!
!
!

10. 5. Communication Design: Diagnostic Tool Product Launches !
"#$%&''' ()*+,-./01)*
Case Study: iC42
i
HyperION
clinical research & development
intelligent sample kits

11. !
"#$%&''' ()*+,-./01)*
Case Study: Book Illustrations

12. 4. Communication Design : Medical Book Illustrations
Proteomics and the Kidney 105 Proteomics and the Kidney 107
Figure 4.1 Time-dependency of kidney tubular epithelium injury and molecular
markers in urine.13,14 Injury will affect cell function before histological and patho-
physiological damage can be detected. At an early point in the process, this is re ected
in protein and metabolite patterns in urine, as absorption and excretion are altered,
repair proteins are formed and cells release proteins into urine. The resulting extent of
urine metabolite and protein pattern changes depends on the intensity of the injury
and how many cells/tubules are affected. Proteins that have been found to be changed
in urine and that may serve as early kidney injury markers are listed in Table 4.5 and are
shown in Figure 4.4. As increasing numbers of cells die by necrosis and/or apoptosis,
the biochemical phase of injury will progress towards the symptomatic phase. These
cells will release at least some of their contents, such as metabolites, proteins, RNA and
DNA, into the urine. Cell death will also trigger secondary reactions such as in am-
mation and brosis. Once this occurs, a complete recovery may no longer be possible.
The injury results in histological changes and kidney function will be reduced. It is not
until the symptomatic phase that currently established diagnostic markers such as
serum creatinine concentrations and blood urea nitrogen will signi cantly change.
Figure 4.2 Proteomics sample analysis.17 Proteomics analysis is a multiple step
procedure that typically involves sample preparation, pre-separation and/or digestion,
During the biochemical stage, changes in gene expression, protein ionization, mass spectrometry analysis, protein identi cation, biostatistics and anno-
expression and biochemical profiles occur, but the cells and organs are still tation. Proteomics strategies can be divided into ‘bottom up’ and ‘top down’
approaches. Bottom up approaches are most frequently used and involve digestion of
able to compensate for this. At this stage, an injury process should be
the proteins of interest and, after mass spectrometry analysis, identi cation of proteins
detectable if sufficiently sensitive assays are available. During the bioche- using database searching based on the detected peptides. Top down proteomics does
mical phase, no notable histological damage has occurred, and the disease not involve a digestion step and analyses the intact proteins. As discussed, both
process may be fully reversible if an appropriate therapeutic intervention is strategies have their advantages and limitations.
available.

13. Metabolomics and the Kidney 45 90 Uwe Christians, Jeska Albuisson, Jost Klawitter and Jelena Klawitter
Figure 3.6 The role of metabolomics and metabolomics-derived combinatorial
metabolite markers for individualized medicine and molecular epidemiology.
Figure 3.1 Interactions between the mammalian system, the microbial metabolome,
diet and environment.13
information into robust and meaningful clinical information. Another
problem is that most of the hundreds and thousands of data points generated
defined as biological compounds that are generally hydrophobic in nature
are not relevant to the disease or drug effect. Instead of conveying additional
and soluble in organic solvents. Lipids are membrane components, medi-
information they only cause random statistical noise including falsely
ators in cell signaling and are utilized as fuel and energy storage.15 Their positive results and may mask valid information. However, while non-
distinct solubility properties often require separate extraction and analysis in targeted ‘omics’ technologies are mostly hypothesis-generating technolo-
metabolomics experiments.14 gies, this information is valuable to develop new targeted diagnostic
The metabolome is considered the most predictive phenotype and holds strategies and tools.163
the promise to extensively contribute to the understanding of phenotypic A ‘bottom up’ approach will start with metabolite markers already
changes as an organism’s answer to disease, genetic changes, and nutritional, established in clinical practice and will look at them not as single markers but
toxicological, environmental and pharmacological influences.4 Another will combine them into patterns. New markers that may have been
advantage of metabolomics is that in contrast to genes and proteins, discovered using non-targeted metabolomics-based discovery may be
metabolites are often tissue- and species-independent. This facilitates added. This will result in the development of ‘combinatorial biomarkers’.
translation of molecular markers strategies from bench-to-bedside or vice Those are molecular marker patterns that typically consist of 3e10 indi-
versa,12 which is of advantage for drug development and molecular marker vidual parameters.164 In general, specific combinatorial biomarker patterns
qualification (see below). Also, while it may take hours, days and sometimes confer significantly more information than a single measurement and, thus,
weeks for protein and mRNA expression to change in response to a chal- can be expected to have better specificity and sensitivity than clinical
lenge, metabolic responses can often be measured within seconds or chemical and biochemical markers currently used in nephrology. Such
minutes.4

14. 4. Communication Design : Medical Book Illustrations
108 Uwe Christians, Stephanie McCrery, Jost Klawitter and Jelena Klawitter Proteomics and the Kidney 111
Figure 4.3 Main proteomics strategies.2 The goal of comparative approaches is to
detect differences between samples and, therefore, requires semi-quantitative
comparison. Descriptive studies are usually qualitative and provide information about
which proteins are present in a de ned sample. In either approach, study designs can
Figure 4.4 Protein markers of kidney injury and their mapping to the nephron.
be pathway- or non-pathway-driven. Pathway-driven studies are targeted e they focus
Potential marker proteins frequently mentioned in the literature are shown. Thus, this
on selected speci c pathways, a protein interaction network or a speci c sub-
list should not be considered complete. The mapping represents the most abundant
population of proteins. Some previous knowledge or a hypothesis is required. By
locations; however, in the case of some proteins, this may be an over-simpli cation. For
contrast, no prior biological knowledge is used in the design of non-pathway-driven or
more information about these proteins, please see Table 4.5, page 142.
non-targeted studies. Global analysis is undertaken (although steps are usually taken to
reduce sample complexity) and the data generated can be regarded as hypothesis-
generating. Most clinical protein marker discovery studies have been non-targeted and intracellular osmolyte concentrations (NUP88) and tight junction integrity
comparative, and they identify proteins differing between study groups. Often such
(MUPP1).22 As indicated, these distinct functions require the expression of
studies do not produce protein identities, but generate algorithms to classify samples
on the basis of protein separation pro les (‘ ngerprinting’). The output in descriptive specific sets of proteins. Exact knowledge of these distinct proteomes will not
studies is a list of proteins. This list typically represents the catalogue of all proteins only allow for characterizing the type of injury and yield information
detectable with a particular technology.2 regarding the associated mechanisms, but also for locating the injury. As
shown in Figure 4.4, patterns of protein kidney injury markers can be
Proteomics inherently is a hypothesis-generating discovery technology. mapped in the nephron.
Proteomic studies can be classified as comparative studies that try to establish As urine can harbor proteins from all kidney subproteomes, and the
quantitative or qualitative protein differences between samples and protein composition of urine is perturbed by kidney injury or disease, the
descriptive studies that focus on the identification of proteins2 (Figure 4.3). urine proteome can subsequently signal the status of kidney health as well as
In both cases, the study designs can be either pathway-driven (targeted) or

15. !
"#$%&''' ()*+,-./01)*
Case Study: stephanie O.
stephanie .
stephanie O. logo white/Grey PDF
Size: 6.6869” W x 1.7671” H
Typeface: Raleway Thin
Color: White
O logo: Grey, stroke .25

16. !
"#$%&''' ()*+,-./01)*
! Strategy: To become a leader in Denver Fashion. stephanie O. to
become a black label (custom line) and white label (ready-to-wear
line). Opportunity: Black label start’s as a custom suiting line
and the white label to be a high-fashion ready to wear travel
collection. Once these have reached success, develop further by
Case Study: stephanie O.
introducing a bridal collection under the black label and fragrance
line under the white label to compliment the stephanie O. brand
conversation.
! Develop Identity: Brand: stephanie O.
Colors: White, Black, Gray
Typography: Raleway Thin
! Brand Mission: Designs for the fashionable, modern woman
!
stephanie O. Community
Black Label:
Age Demographic: All ages
Fashionable, Modern Women
Successful Career Women
stephanie .
Collage Graduates Interviewing
Brides
Bridal Party
Mother of the Bride
Special Occasion
White Label:
Age Demographic stephanie O. logo white/Grey PDF
Fashionable, Modern Women Size: 6.6869” W x 1.7671” H
Travel Fashionista’a Typeface: Raleway Thin
Color: White
Weekend Fashionista’s O logo: Grey, stroke .25

17. ! Communication Design: Business Cards & Price Tags
stephanie O. business card design layout and specifiations
!
"#$%&''' ()*+,-./01)*
Case Study: stephanie O.
3 1/2”
Business Card (front)
stephanie O. design
Size: 1.75” x 3.5”
Typeface: Raleway Thin
Logo: Custom O
5. Communication Design: Fashion Labels
stephanie O. clothing label design specifications
stephanie .
1 3/4” Clothing: Black Label
Custom and Trunk Show Pieces
stephanie .
Size: 1.5”W x .5”H
Typeface: Raleway Thin
ready to wear fashion
Business Card (back) Typeface Color: White
stephanie O. design O logo color: Light Grey, stroke .25
Color background: Black
Size: 1.75” x 3.5”
Typeface: Raleway Thin
Logo: Custom O
Clothing: White Label
stephanie . Ready to Wear
Size: 1.5”W x .5”H
Typeface: Raleway Thin
Typeface Color: Black
O logo color: Light Grey, stroke .25
stephanie Ohnmacht Color background: White
303.549.5320
stephanie@stephanieodesigns.com

18. !
"#$%&''' ()*+,-./01)*
Case Study: The Room Tailor

19. !
"#$%&''' ()*+,-./01)*
! Strategy: To become a leader in Interior Design Consultation.
Opportunity: Create a brand identity to compliment The Room
Tailor, that attracts new business. Marketing design recommended:
“At your Service” door hangers and custom design canvas totes for
clients.
Case Study: The Room Tailor
! Develop Identity: Brand: The Room Tailor
Colors: Custom
Typography: Pilo Thin
! Brand Mission: “the art of living.”
! The Room Tailor Community
Homeowners selling their homes
First time homebuyers
Contractors
Architects
Interior Design Showrooms
Real Estate Agents
Wedding Planners

20. ! Communication Design: Business Cards !
"#$%&''' ()*+,-./01)*
Case Study: The Room Tailor
Business Cards
Size: 2.5” x 2.5” print 50 of each color
the art of living the art of living the art of living the art of living the art of living
Front Side
conni newsome conni newsome conni newsome conni newsome conni newsome
720.422.8235 720.422.8235 720.422.8235 720.422.8235 720.422.8235
Backside

21. Communication Design: Postcard !
"#$%&''' ()*+,-./01)*
Case Study: The Room Tailor
the art of living

22. Communication Design: Custom Stamp & Ink Colors
!
"#$%&''' ()*+,-./01)*
Case Study: The Room Tailor
Pantone Solid to Process 262 EC
Pantone Process DS159-2C
Pantone Metallic Coated 877 C
Pantone Color Bridge CMYK EC 2955 EC
Pantone Solid Matte 124 M

23. !
"#$%&''' ()*+,-./01)*
Case Study: Blues

24. !
"#$%&''' ()*+,-./01)*
! Strategy: To become a leader in creative concept development.
Opportunity: Target the tea and coffee industry.
Case Study: The Room Tailor
! Develop Identity: Brand: Blues
Colors: Custom
Typography: Optima
! Brand Mission: creative + concept + development
! Blues Community
Tea Cafe’s
Coffee Cafe’s
Small Business
Start Up’s
Tea & coffee product development
Retail

25. ! Communication Design: Creative Concept Development Menu "#$%&''' ()*+,-./01)* !
Case Study: Blues
$*#-%&'# 3 $),$#4% 3 1#'#.)4/#,%
!"#$%&'#()$"*#%&+,
( ( ( !""#$%&'#()*&+&,-.(/-*0#%&,+(((((((((
L"$+:(3#'#06GD#+%
( 1#2&+,(3(4*)/)%&),($-/4-&+,25 !6+2#G%(3#'#06GD#+% ( ( ( E1#,%&"8&,+(3($*#-%&,+($*#-%&'#(
-"&'$%#(.$/#0&+,(1(-$2*$,&+,(3#4&,+( ( ( ( D#'#.)4(-(,#<(*#%-&.($;-&,(3( ( $),$#4%25
( 6#&,'&+)*-%#(7*-,1(.)8-.%85 ( $),2:/#*(7*-,15 )$"*#%(=#4#$"2A( (
56&+%7)$"*#%&+,(800&$+2#4 HGG6"%>+&%<(8+$0<4&4 ( K,1#*2%-,1($),2:/#*2(3(
( ( ( 9*#-%#(2:$$#22":.($)..-7)*-%&),2( ( ( ( >*#,1(E1#,%&=&$-%&),(3(-,-.82&25 ( 4)2&%&),($.&#,%2(%)(7#(*#%-&,#15
( %;-%(-..)<(8):*(7*-,1(%)(=.):*&2;5 .&?#4%<0#()$"*#%&+, ;$0#4(3#'#06GD#+%( (
966:(;%<0&+, ( !2%-7.&2;(3(1#=&,#(%;#($)*#( ( !'-.:-%#($)/4#%&%&),(3(1#'#.)4(
( ( ( (>-0#(4*#2#,%-%&),(%)(- ( '-.:#2()"(8):*(7*-,1(%)($*#-%#( ( #""#$%&'#(2%*-%#+&#25
( ( ( ($)/4#%&%&'#(.#'#.5 ( $:2%)/#*(.)8-.%85 ;$0#4(;>GG6"%(
=#4%$>"$+%(1(!$?@()#"2A$+:&4&+,( ;%"$%#,&2(-0$++&+,
( G*)"#22&),-..8(*#4*#2#,%($.&#,%2(
( ?#%('&2:-.(4#*$#4%&),(#,;-,$#( ( ( ( E1#,%&"8(,#<(/-*0#%2A(.)$-%&),2(
( -%(":,$%&),2A(%*-1#("-&*2(3(
( 8):*(7*-,15 ( 3(#@4-,2&),()44)*%:,&%&#25
( /##%&,+25
=#%$&0(3#4&,+(1(.$<6>% =#%$&0(9"$+2A&4&+,
;$0#4(B"$&+&+,
( ( ( 9*#-%#(-,(#,+-+&,+(24-$#(%;-%( ( F22&2%(-,(#@&2%&,+(*#%-&.($;-&,(%)(
( ( ( >*-&,(<;).#2-.#(2-.#2(2%-""(3(
( 2:44)*%2(8):*(7*-,1(#@4#*&#,$#5 ( "*-,$;&2#5
9&+$+2&$0(;#"'&2#4 ( 1&2%*&7:%)*2(%)(7#$)/#(/)*#(
!"#$%#(B6(;$'6" ( #""#$%&'#(<&%;L(
( ( ( ?#-*,(%;#(-*%()"("))1(4-&*&,+5 ( ( ( G*)H#$%(%;#(4*)=&%(4)%#,%&-.()"(
( ,#<(3(#@&2%&,+(.)$-%&),25 ( J#*'&$#(J%-,1-*12
=#%$&0(;&,+$%>"#(C%#D4 ( >#-M*&2%-(>*-&,&,+
( ( ( 9*#-%&'#(2&+,-%:*#(/#,:(&%#/25 )#",#"4(I(82J>&4&%&6+4
( N-*&2%-(>*-&,&,+
)#:&$(-0$++&+, ( ( ( G:*$;-2#(3(2#..(.)$-%&),I25 5 ( ( N:&.1&,+(!""#$%&'#(%#-/4
( ( 9*#-%#(/#1&-(-,1(#'#,%(4.-,2A( K>$0&%<(8+$0<4&4
-"62#44(CDG"6'#D#+%
( ( %;#,(2##(%;*):+;(&%2(#@#$:%&),5 ( ( ( E/4*)'#(%-2%#(3(C:-.&%85 ( J:$$#22":.()4#*-%&),2(&2(%;#(0#8(
E#,6%&$%&6+ )#+>(;%"$%#,< ( %)(.),+#'&%85
( ( ( B#+)%&-%#($.&#,%(-,1(1&2%*&7:%)*( ( ( ( J#%(/#,:(2%*-%#+8(3(4*&$#25 M'#+%()$"*#%&+,
( -+*##/#,%2(<&%;("-')*-7.#( ( D#'#.)4(3(-1/&,&2%*-%#(
( *#2:.%25 ( $)/4-,8(#'#,%2(3$)/4#%&%&),25
90$'6"(-"6F&0#(3#'#06GD#+%
( ( ( 9*#-%#(:,&C:#(=.-')*(4*)=&.#25
choose blues, contact Paul at 303- 775-3856